Molecular origins and impact of APOBEC3 mutagenesis in cancer

APOBEC3 突变的分子起源和对癌症的影响

基本信息

  • 批准号:
    10693177
  • 负责人:
  • 金额:
    $ 40.94万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-09-01 至 2027-08-31
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY Mutations arise as a result of exogenous and endogenous processes that leave characteristic imprints or signatures upon the genome. Systematic analysis of these mutational signatures led to the identification of >50 distinct types of single base substitutions (SBS) in human cancer genomes. Revealing the origins of individual signatures is critical for understanding cancer etiology, with potential implications for cancer prevention and therapy. Two of the most prevalent mutational signatures in cancer, termed SBS2 and SBS13, are present in >78% of cancer types and 56% of all cancer genomes, with a particular prominence in breast, bladder, and lung cancers. SBS2 and SBS13 are proposed to be caused by the endogenous APOBEC3 (A3) enzymes, which target ssDNA and RNA of viruses and retroelements as part of the innate immune defense. Correlations between A3 expression, driver gene mutations in A3-preferred contexts, and clinical outcomes suggest that A3 mutagenesis may play important roles in cancer etiology and evolution. Thus, there is strong rationale to understand the mechanisms of A3 activity. However, reliance on engineered model systems and correlative data have caused links between A3 enzymes, mutations in cancer, and cancer etiology to be poorly understood. We have identified human cancer cell lines with endogenous A3 mutagenesis and developed a workflow that enables us to quantify contributions of individual A3 members to mutations. Here, we propose to leverage this workflow to accomplish the following goals: 1) Identify A3 mutator enzymes in cancer types where A3 mutagenesis is prevalent and find biomarkers of their activity; 2) Investigate mechanisms modulating A3 mutagenesis; 3) Determine the functional relevance of A3 mutagenesis in therapy resistance and metastasis. Aim 1 will expand upon our characterization of human cancer cells with active A3 mutagenesis to identify A3 mutators in breast, bladder, and lung cancers. In parallel, we will directly assess the unknown specificity and sensitivity of assays to measure activities of individual A3 enzymes. These experiments may further confirm the speculative A3-etiology of a large number of cancer mutations and quantify contributions of individual A3 enzymes, thus nominating them as putative targets for therapeutic pursuit. Aim 2 builds on our preliminary data to investigate proposed modulators of A3 mutagenesis. These experiments have the potential to broaden the scope of therapeutic opportunities focused on cancer cell evolution. Aim 3 will assess the links between A3 enzymes, therapy resistance and metastasis in breast, bladder, and lung cancer cell lines. These experiments will test predictions from multi-dimensional associations that A3-mutagenesis is a disease-modifying process that can be therapeutically exploited at various stages of cancer evolution. Taken together, these studies will define the etiologies of highly prevalent mutational processes and identify strategies to elicit more durable clinical benefits to targeted therapies and curb metastasis.
项目总结

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

JOHN MACIEJOWSKI其他文献

JOHN MACIEJOWSKI的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('JOHN MACIEJOWSKI', 18)}}的其他基金

Immune control and genomic instability at micronuclei
微核的免疫控制和基因组不稳定性
  • 批准号:
    10365554
  • 财政年份:
    2022
  • 资助金额:
    $ 40.94万
  • 项目类别:
Immune control and genomic instability at micronuclei
微核的免疫控制和基因组不稳定性
  • 批准号:
    10544747
  • 财政年份:
    2022
  • 资助金额:
    $ 40.94万
  • 项目类别:
The origins of chromosome rearrangement in the cancer genome
癌症基因组中染色体重排的起源
  • 批准号:
    9352813
  • 财政年份:
    2016
  • 资助金额:
    $ 40.94万
  • 项目类别:
The origins of chromosome rearrangement in the cancer genome
癌症基因组中染色体重排的起源
  • 批准号:
    9223946
  • 财政年份:
    2016
  • 资助金额:
    $ 40.94万
  • 项目类别:

相似海外基金

Roles of immune cells derived from clonal hematopoiesis in B-cell lymphomas
克隆造血来源的免疫细胞在 B 细胞淋巴瘤中的作用
  • 批准号:
    24K19213
  • 财政年份:
    2024
  • 资助金额:
    $ 40.94万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Identification of novel biomarkers for EBV-associated B-cell lymphomas arising in the oral cavity
口腔中出现的 EBV 相关 B 细胞淋巴瘤的新型生物标志物的鉴定
  • 批准号:
    23K15982
  • 财政年份:
    2023
  • 资助金额:
    $ 40.94万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Chromunities Drive Transcriptional Reprogramming in Humoral Immunity and B-cell Lymphomas
染色体驱动体液免疫和 B 细胞淋巴瘤中的转录重编程
  • 批准号:
    10606730
  • 财政年份:
    2023
  • 资助金额:
    $ 40.94万
  • 项目类别:
Curing Through Collaboration: Utilizing Cooperative Groups in the Fight Against Chronic Lymphocytic Leukemia and B-cell Lymphomas
通过合作进行治愈:利用合作团体对抗慢性淋巴细胞白血病和 B 细胞淋巴瘤
  • 批准号:
    10566833
  • 财政年份:
    2023
  • 资助金额:
    $ 40.94万
  • 项目类别:
Curing Through Collaboration: Utilizing Cooperative Groups in the Fight Against Chronic Lymphocytic Leukemia and B-cell Lymphomas
通过合作进行治愈:利用合作团体对抗慢性淋巴细胞白血病和 B 细胞淋巴瘤
  • 批准号:
    10987699
  • 财政年份:
    2023
  • 资助金额:
    $ 40.94万
  • 项目类别:
Synthetic lethal targeting of EBV-positive diffuse large B cell lymphomas in persons living with HIV
HIV 感染者 EBV 阳性弥漫性大 B 细胞淋巴瘤的合成致死靶向
  • 批准号:
    10541285
  • 财政年份:
    2022
  • 资助金额:
    $ 40.94万
  • 项目类别:
Role of Epstein-Barr virus LMP2A protein in maintaining oncogenic IgM signaling in EBV+ B cell lymphomas
Epstein-Barr病毒LMP2A蛋白在维持EBV B细胞淋巴瘤中致癌IgM信号传导中的作用
  • 批准号:
    10540952
  • 财政年份:
    2022
  • 资助金额:
    $ 40.94万
  • 项目类别:
Synthetic lethal targeting of EBV-positive diffuse large B cell lymphomas in persons living with HIV
HIV 感染者 EBV 阳性弥漫性大 B 细胞淋巴瘤的合成致死靶向
  • 批准号:
    10703446
  • 财政年份:
    2022
  • 资助金额:
    $ 40.94万
  • 项目类别:
Therapeutic potential of novel antibody-oligonucleotide conjugate for intractable B-cell lymphomas
新型抗体-寡核苷酸缀合物治疗难治性 B 细胞淋巴瘤的潜力
  • 批准号:
    22K08497
  • 财政年份:
    2022
  • 资助金额:
    $ 40.94万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Role of Epstein-Barr virus LMP2A protein in maintaining oncogenic IgM signaling in EBV+ B cell lymphomas
Epstein-Barr病毒LMP2A蛋白在维持EBV B细胞淋巴瘤中致癌IgM信号传导中的作用
  • 批准号:
    10707312
  • 财政年份:
    2022
  • 资助金额:
    $ 40.94万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了